IPO Timeline Raw facts
Broker Deadline
2025-11-03
Morning deadline
HKEX Deadline
2025-11-03
Noon deadline
Broker Results (T-2)
2025-11-04
Some brokers release in afternoon
Grey Market (T-1)
2025-11-05
Afternoon
HKEX Allotment (T-1)
2025-11-05
Evening
Registrar Allotment (T-1)
2025-11-05
Evening
Listing Day (T)
2025-11-06
First day of trading
Company Overview
| Stock Name | Vigonvita-B |
|---|---|
| Stock Code | 02630 |
| Company Full Name | Vigonvita Life Sciences Co., Ltd. |
| Industry | Biotech & Pharma |
| Principal Activities | introduction of our Core Products and VV116: (cid:129) LV232 |
| Listing Date | 2025-11-06 |
| Listing Rules Era | New Rules (after Aug 2025) |
| Listing Rules Chapter | Chapter 18A |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | No. 108, Yuxin Road Suzhou Industrial Park District Suzhou, PRC |
| Business Address (Hong Kong) | 香港銅鑼灣勿地臣街1號時代廣場2座31樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.vigonvita.cn |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | Computershare Hong Kong Investor |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism B |
|---|---|
| Offer Price | HK$ 33.37 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 200 shares |
| Entry Threshold | HK$ 6,673 |
| Par Value | RMB 1.0 / shares |
| Offer Period | 2025-10-28 to 2025-11-03 |
| Global Offering Shares | 17,597,800 shares |
| HK Public Offer Shares (Initial) | 1,759,800 shares (10.0%) |
| Public Offer Lots (Initial) | 8,799lots (4,399lots, 4,400lots) |
| International Placing Shares (Initial) | 15,838,000 shares (90.0%) |
| Offer Ratio | ~10.5% |
| Total Shares Post-IPO | 167,597,800 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | CITIC Securities (Hong Kong) Limited CE AAK249 |
| Cornerstone Share | No cornerstone investors |
| Clawback Tiers | Mechanism B: no clawback |
| Reallocation Option | No |
| Total Global Offering Size | HK$ 587,238,586 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 200 | HK$ 6,674 |
| 2 lots | 400 | HK$ 13,348 |
| 3 lots | 600 | HK$ 20,022 |
| 4 lots | 800 | HK$ 26,696 |
| 5 lots | 1,000 | HK$ 33,370 |
| 6 lots | 1,200 | HK$ 40,044 |
| 7 lots | 1,400 | HK$ 46,718 |
| 8 lots | 1,600 | HK$ 53,392 |
| 9 lots | 1,800 | HK$ 60,066 |
| 10 lots | 2,000 | HK$ 66,740 |
| 15 lots | 3,000 | HK$ 100,110 |
| 20 lots | 4,000 | HK$ 133,480 |
| 25 lots | 5,000 | HK$ 166,850 |
| 30 lots | 6,000 | HK$ 200,220 |
| 35 lots | 7,000 | HK$ 233,590 |
| 40 lots | 8,000 | HK$ 266,960 |
| 45 lots | 9,000 | HK$ 300,330 |
| 50 lots | 10,000 | HK$ 333,700 |
| 75 lots | 15,000 | HK$ 500,550 |
| 100 lots | 20,000 | HK$ 667,400 |
| 125 lots | 25,000 | HK$ 834,250 |
| 150 lots | 30,000 | HK$ 1,001,100 |
| 175 lots | 35,000 | HK$ 1,167,950 |
| 200 lots | 40,000 | HK$ 1,334,800 |
| 225 lots | 45,000 | HK$ 1,501,650 |
| 250 lots | 50,000 | HK$ 1,668,500 |
| 300 lots | 60,000 | HK$ 2,002,200 |
| 350 lots | 70,000 | HK$ 2,335,900 |
| 400 lots | 80,000 | HK$ 2,669,600 |
| 450 lots | 90,000 | HK$ 3,003,300 |
| 500 lots | 100,000 | HK$ 3,337,000 |
| 600 lots | 120,000 | HK$ 4,004,400 |
| 700 lots | 140,000 | HK$ 4,671,800 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 800 lots | 160,000 | HK$ 5,339,200 |
| 900 lots | 180,000 | HK$ 6,006,600 |
| 1,000 lots | 200,000 | HK$ 6,674,000 |
| 1,250 lots | 250,000 | HK$ 8,342,500 |
| 1,500 lots | 300,000 | HK$ 10,011,000 |
| 1,750 lots | 350,000 | HK$ 11,679,500 |
| 2,000 lots | 400,000 | HK$ 13,348,000 |
| 2,250 lots | 450,000 | HK$ 15,016,500 |
| 2,500 lots | 500,000 | HK$ 16,685,000 |
| 3,000 lots | 600,000 | HK$ 20,022,000 |
| 3,500 lots | 700,000 | HK$ 23,359,000 |
| 4,000 lots | 800,000 | HK$ 26,696,000 |
| 4,399 lots | 879,800 | HK$ 29,358,926 |
Stock Connect Inclusion
| HK Market Cap | HK$ 14.06B |
|---|
| 26Q2 Regular Review | |
| Inclusion Pathway | 18A Biotech |
|---|---|
| Est. Threshold | HK$ 10.47B Met |
| Analysis Result | 预计2026年9月7日入通 |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 5,592,738,586 |
|---|---|
| H-Share Market Cap (at Offer Price) | HK$ 2,225,015,928 |
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not applicable (loss-making) |
| Profit/Loss Status | Net loss RMB217.6 million |
| Period-End Cash Balance | RMB 121.14 million |
| Listing Expenses | ~HK$ 59,600,000 |
| Listing Expenses / Funds Raised | ~10.3% |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 82.0 |
|---|---|
| First Day Open | HK$ 95.0 |
| First Day Change | 145.73% |
| First Day Volume | 5534410.0 |
| First Day Turnover | 486174000.0 |
Use of Proceeds
| Use of Proceeds | 1、38.0%（或約198.0百萬港元）將用于我們核心產品的研發； 2、27.0%（或約140.7百萬港元）將用于我們其他候選產品的研發； 3、10.0%（或約52.1百萬港元）將用于建設我們的青島工廠； 4、15.0%（或約78.2百萬港元）將用于強化我們的銷售及營銷能力； 5、10.0%（或約52.1百萬港元），將用于營運資金及其他一般公司用途。 |
|---|
Underwriting Syndicate
Sole Sponsor (1)
CITIC Securities (Hong Kong) Limited CE AAK249(sole)
Sponsor cum Overall Coordinator (1)
CLSA Limited CE AAB893
Overall Coordinators (4)
Joint Global Coordinators (4)
Joint Bookrunners (9)
CLSA Limited CE AAB893
China International Capital Corporation Hong Kong Securities Limited CE AEN894
ABCI CAPITAL LIMITED CE AWL249
China Galaxy International Securities (Hong Kong) Co., Limited CE AXM459
CCB International Capital Limited CE AJO225
CHINA EVERBRIGHT SECURITIES (HK) LIMITED CE AAW536
Futu Securities International (Hong Kong) Limited CE AZT137
Tiger Brokers (HK) Global Limited CE BMU940
ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855
Joint Lead Managers (9)
CLSA Limited CE AAB893
China International Capital Corporation Hong Kong Securities Limited CE AEN894
ABCI Securities Company Limited CE ACX411
China Galaxy International Securities (Hong Kong) Co., Limited CE AXM459
CCB International Capital Limited CE AJO225
CHINA EVERBRIGHT SECURITIES (HK) LIMITED CE AAW536
Futu Securities International (Hong Kong) Limited CE AZT137
Tiger Brokers (HK) Global Limited CE BMU940
ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855
Capital Market Intermediaries (10)
CLSA Limited CE AAB893
China International Capital Corporation Hong Kong Securities Limited CE AEN894
ABCI CAPITAL LIMITED CE AWL249
ABCI Securities Company Limited CE ACX411
China Galaxy International Securities (Hong Kong) Co., Limited CE AXM459
CCB International Capital Limited CE AJO225
CHINA EVERBRIGHT SECURITIES (HK) LIMITED CE AAW536
Futu Securities International (Hong Kong) Limited CE AZT137
Tiger Brokers (HK) Global Limited CE BMU940
ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855
Stabilizing Manager (1)
CITIC Securities (Hong Kong) Limited CE AAK249
Service Providers
| Role | Institution |
|---|---|
| Legal Advisor to Company |
美迈斯律师事务所 Jun He Law Offices Jingtian & Gongcheng |
| Legal Advisor to Sponsors/Underwriters |
苏利文•克伦威尔律师事务所（香港）有限法律责任合伙 King & Wood |
| Auditor and Reporting Accountant | 德勤•关黄陈方会计师行 |
| Industry Advisor | 灼识行业咨询有限公司 |
| Compliance Advisor | Somerley Capital Limited CE BAU754 |
| Receiving Banks |
Bank of China (Hong Kong) Limited China CITIC Bank International Limited |
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Chairman | Dr. Tian Guanghui |
|---|---|
| Company Secretary | Ms. Guo Ting |
Executive Director (2)
| # | Name | English Name | Type |
|---|---|---|---|
| 1 | 田广辉 | — | Executive Director |
| 2 | 胡天文 | — | Executive Director |
Non-Executive Director (1)
| # | Name | English Name | Type |
|---|---|---|---|
| 1 | 刘浩轩 | — | Non-Executive Director |
Independent Non-Executive Director (6)
| # | Name | English Name | Type |
|---|---|---|---|
| 1 | 鞠佃文 | — | Independent Non-Executive Director |
| 2 | 曹新文 | — | Independent Non-Executive Director |
| 3 | 徐宏喜 | — | Independent Non-Executive Director |
| 4 | 杨汝磊 | — | Independent Non-Executive Director |
| 5 | 周洪举 | — | Independent Non-Executive Director |
| 6 | 李建 | — | Independent Non-Executive Director |
Major Shareholders
| Major Shareholders & Holdings | Dr. Shen holds 82,461,110 unlisted shares (representing 49.20%), Ms. Jin Jie holds 2,272,478 unlisted shares (representing 1.36%), Dr. Tian holds 5,726,644 unlisted shares and 8,589,967 H shares (in total representing 8.54%), Suzhou Hesheng holds 6,783,348 H shares (representing 4.05%), Ms. Jin Qing holds 5,517,145 H shares (representing 3.29%), Xieyao Kexin holds 4,370,157 H shares (representing 2.61%), Xieyao Kesheng holds 1,032,546 H shares (representing 0.62%), Suzhou Meilingge holds 1,092,539 H shares (representing 0.65%), other pre-IPO investors in total hold 13.34%, and public shareholders hold 10.50%. |
|---|
AI
AI 市场洞察
AI interpretation
deepseek-v4-pro · AI-generated
市场情绪
The IPO saw extraordinary market enthusiasm with an oversubscription ratio of 6238.42x, indicating intense demand for the shares. The overall hit rate of just 3.32% reflects a very low allocation probability for retail investors, typical of highly sought-after biotech listings under Chapter 18A. Final pricing at HK$33.37 likely captured strong institutional interest, though the absence of an indicative range limits pricing insight. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
申购档位分析
Tier-specific allocation data is not provided, preventing any analysis of distribution patterns or potential anomalies such as 甲尾-乙头 inefficiencies. Without detailed breakdowns of lots applied and allocated per tier, it is impossible to assess broker fee efficiency or unusual winner ratios at key thresholds. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
申购人群画像
The demographic data for this IPO is not available; all recorded percentages for mainland and Hong Kong participation show zero, likely indicating missing or unreported figures. Consequently, no conclusions can be drawn about regional concentration, gender distribution, or Mainland China participation rates. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
